Small modular immunopharmaceutical
From Wikipedia, the free encyclopedia
"SMIP" redirects here. For the school called Sekolah Menengah Ismail Petra, see SMS Tengku Muhammad Faris Petra.
Small modular immunopharmaceuticals, or SMIPs for short, are artificial proteins that are intended for use as pharmaceutical drugs. They are largely built from parts of antibodies (immunoglobulins), and like them have a binding site for antigens that could be used for monoclonal antibody therapy. SMIPs have similar biological half-life and, being smaller than antibodies, are reasoned to have better tissue penetration properties. They were invented by Trubion and are now being developed by Emergent BioSolutions, which acquired Trubion in 2010.[1]